A Phase II trial evaluated the safety, efficacy and side-effect profile of three different dosing regimens of the albiglutide. This was a randomized, double-blind trial enrolling 356 subjects with ...
Longer-acting glucagon-like peptide-1 (GLP-1) receptor agonists and devices have been recently developed and include once-weekly exenatide, dulaglutide, albiglutide, semaglutide and miniosmotic ...